Wall Street Loves Eli Lilly (LLY) Stock: Two Upgrades, One Clear Direction
TLDR
- Citigroup analyst Geoff Meacham set a Street-high $1,600 price target on LLY, implying 45% upside from current levels.
- Berenberg upgraded LLY to Buy and raised its price target to $1,400, citing ~25% upside potential.
- LLY currently trades at $1,138, up 2% on the day.
- Eli Lilly holds a 60% global market share in weight-loss drugs, with combined quarterly sales of $14.9 billion for its obesity and diabetes treatments.
- LLY carries a consensus Strong Buy rating from 20 Wall Street analysts, with an average price target of $1,375.78.
Eli Lilly stock is getting attention from multiple directions today, with two separate Wall Street upgrades landing within 24 hours.
Citigroup analyst Geoff Meacham set a $1,600 price target on LLY, the highest on Wall Street. That implies about 45% upside from the stock’s current price of $1,138.
Meacham, a five-star rated analyst with a 59% success rate, reiterated a Buy rating alongside the target. He pointed to Eli Lilly’s dominance in the weight-loss drug market as a key reason for his bullish stance.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
